NCT00003041已完成2 期
Phase II Evaluation of Pyrazoloacridine (NSC #366140) in Patients With Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 10
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating women who have refractory metastatic breast cancer.
详细描述
OBJECTIVES: I. Determine the efficacy of pyrazoloacridine in patients with refractory breast cancer. II. Determine the toxic effects of pyrazoloacridine in these patients.
OUTLINE: Patients receive pyrazoloacridine IV over 3 hours. Treatment repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 1 year.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye MelanomaIntraocular MelanomaMelanoma (Skin)NCT00003802Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
已完成
2 期
Pyrazoloacridine in Treating Women With Metastatic Breast CancerBreast CancerNCT00002585Barbara Ann Karmanos Cancer Institute20
已完成
2 期
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung CancerLung CancerNCT00002656Barbara Ann Karmanos Cancer Institute20
撤回
2 期
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney CancerMetastatic CancerLiver CancerNCT00003714M.D. Anderson Cancer Center
已完成
1 期
Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00006355Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins